Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AVXL 01.06.2025

Full Press ReleaseSEC FilingsOur AVXL Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
  • 01.13.2025 - New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
  • 01.06.2025 - Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.23.2024 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com